Tenderwize
Zurück zur Suche

Open-house rebate agreement for Ublituximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 187 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ublituximab, ATC L04AG14

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for pharmaceutical products containing Ublituximab (ATC L04AG14).
  • Open-house model with uniform conditions for all participants and no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for the active substance Ublituximab (ATC L04AG14) offered by AOK Rheinland-Pfalz/Saarland. It is a non-exclusive, no-selection contract model with uniform terms for all participants, no individual negotiations, and monthly entry possible during the 24-month term. The notice states that this publication is not a public contract in the sense of procurement law, but it is published in TED for transparency. No contract value is provided.

Risiken

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only authorised and legally marketable medicines in Germany may be supplied.

Administrative

  • If a medicine is not yet listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreement for Ublituximab

Single lot covering non-exclusive pharmaceutical rebate agreements for medicines containing Ublituximab. The open-house model applies uniform terms to all participating pharmaceutical companies. Children’s medicines listed in the BfArM list under Section 35(5a) SGB V are excluded. Contract start is earliest 2025-05-01, with monthly entry possible during the 24-month period; contracts end no later than 24 months after the earliest start date. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
26 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
196730-2025

Dokumente (1)

Ähnliche Ausschreibungen